On Jul. 27, 2020, the Serum Institute of India announced that it was is conducting phase III clinical trial of recombinant Bacillus Calmette-Guerian vaccine candidate VPM1002 to evaluate its ability in reducing infection and severe disease outcomes of COVID-19 among high-risk persons of advanced age, comorbidities and high-exposure healthcare workers.